Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONO-7914 alone and with nivolumab in advanced solid tumors
NCT06535009Phase 1Terminated
- Sponsor
- Ono Pharmaceutical
- Start
- Feb 2022
- Primary completion
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of ONO-7914 in solid tumor (2 arms), sponsored by Ono Pharmaceutical. Primary endpoints: Dose Limiting Toxicity at 28 days and Adverse Events as assessed by CTCAE v5.0. Started Feb 2022; status: terminated.
02
Drugs
ONO-7914
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06535009.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06535009.